Kevin McCulloch's most recent trade in Xeris Biopharma Holdings Inc was a trade of 25,000 Common Stock done at an average price of $4.4 . Disclosure was reported to the exchange on June 13, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Purchase of securities on an exchange or from another person at price $ 4.38 per share. | 13 Jun 2025 | 25,000 | 1,708,585 (6%) | 0% | 4.4 | 109,475 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.15 per share. | 02 Apr 2025 | 733 | 1,683,585 (6%) | 0% | 5.2 | 3,775 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 500,000 | 500,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 185,000 | 1,684,318 (6%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 48,834 | 1,499,318 (5%) | 0% | 3.6 | 173,849 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.56 per share. | 31 Jan 2025 | 29,300 | 1,548,152 (5%) | 0% | 3.6 | 104,308 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.61 per share. | 03 Jan 2025 | 24,501 | 1,577,452 (5%) | 0% | 3.6 | 88,449 | Common Stock |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 200,000 | 200,000 | - | - | Stock Appreciation Right | |
| Xeris Biopharma Holdings Inc | Kevin McCulloch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 150,000 | 1,601,953 (5%) | 0% | 0 | Common Stock |